



Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(於百慕達註冊成立之有限公司)
(Stock Code 股份代號: 00512)

25 September 2026

Dear registered shareholder(s),

Grand Pharmaceutical Group Limited (the “Company”) – Notice of Availability
- Notice of publication of Interim Report (the “Current Corporate Communication”)

The Current Corporate Communication of the Company has been published in English and Chinese languages and is available on the website of the Company at www.grandpharm.com and the HKEXnews (the “HKEXnews”) website at www.hkexnews.hk.

For the shareholders who have selected to receive the Company’s Corporate Communications (the “**Corporate Communications**”) ^(Note 1) in printed version, enclosed is the Current Corporate Communication of your choice. If you have any difficulty in receiving or gaining access to the Current Corporate Communication posted on the Company’s website for any reason, the Company will promptly upon your notice send the printed version of the Current Corporate Communication to you free of charge; please write to the Company’s Hong Kong share registrar (the “**Share Registrar**”), Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong or by email to grandpharma.ecom@computershare.com.hk.

You are entitled to change the means of receipt of the future Corporate Communications by completing the enclosed reply form (the “**Reply Form**”) and return it by hand or by post, using the mailing label at the bottom of the Reply Form to the Share Registrar (no postage stamp is necessary if posted in Hong Kong; otherwise please affix an appropriate stamp); or you may also send a scanned copy of the Reply Form duly completed and signed to the Share Registrar via email to grandpharma.ecom@computershare.com.hk.

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) under the expansion of paperless listing regime and electronic dissemination of Corporate Communications that came into effect on 31 December 2023, the Company is writing to inform you that the Company has adopted electronic dissemination of Corporate Communications. Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.grandpharm.com and the HKEXnews website at www.hkexnews.hk in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of the latest Corporate Communications, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form. Alternatively, you may sign and return the Reply Form to the Share Registrar.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, you may (i) be unable to receive any notifications regarding the publication of Corporate Communications; (ii) need to proactively check the Company’s website and the HKEXnews website to keep up with the publication of Corporate Communications; and (iii) the Company will send the Actionable Corporate Communications^(Note 2) in printed form in the future.

If you want to receive future Corporate Communications in printed form, please complete the enclosed Reply Form and send it to the Share Registrar or send an email to grandpharma.ecom@computershare.com.hk specifying your name, address and request to receive future Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,
By order of the Board
Grand Pharmaceutical Group Limited
Dr. Tang Weikun
Chairman

Notes:

1. Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.
2. Actionable Corporate Communication is any corporate communication that seeks instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.

* For identification purpose only

REPLY FORM 回條

To: Computershare Hong Kong Investor Services Limited (the “Share Registrar”) 致: 香港中央證券登記有限公司 (「股份過戶處」)
17M Floor, Hopewell Centre 香港灣仔皇后大道東 183 號
183 Queen’s Road East, Wan Chai, Hong Kong 合和中心 17M 樓

(Please **choose ONLY ONE** of the options below)
(請從以下選項中**只選擇其中一項**)

Personalized QR Code
專屬二維碼

Option 1: Provide your email address for receipt of future Corporate Communications[#] of the Company via electronic dissemination by scanning your personalized QR code

選項 1: 掃描 閣下專屬二維碼提供 閣下之電子郵件地址，以接收公司通過電子方式發佈的未來公司通訊[#]

You are **NOT required** to return this Reply Form if you choose Option 1.
如選擇了選項 1，閣下無須交回本回條。

Option 2: I/we hereby provide my/our email address in writing for receipt of future Corporate Communications[#] of the following listed company (the “Company”) via electronic dissemination

選項 2: 本人/吾等現以書面提供本人/吾等之電子郵件地址，以確保收到以下上市公司（「本公司」）通過電子方式發佈的未來公司通訊#

Name of Securities holder(s) 證券持有人姓名：

Name of the listed company 上市公司名稱：

Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*

Email address 電郵地址: (Note 3 / 附註3)

[illegible]

Option 3: I/we hereby request for receipt of Corporate Communications[#] in printed form (Please mark “✓” in the below box if applicable)

選項 3: 本人/吾等現要求收取公司通訊[#]印刷本 (如適用, 請在以下方格內劃上「✓」號)

☐ receive future Corporate Communications[®] in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction. (Note 5)
收取未來公司通訊[®]的印刷本，並已知悉本指示由收取指示日期起計一年內有效。(附註5)

Signature(s): (Note 1)

署名: (附註 1)

Contact number:

聯絡電話號碼:

Date:

日期:

Notes 附註:

Notes 附註:

1. Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.
請清楚填妥 閣下之所有資料。如屬聯名股東，則本回條須由所有聯名股東聯合簽署，方為有效。

2. Any Reply Form with no signature or otherwise incorrectly completed will be void.
任何回條若未有簽署或在其他方面填寫不正確，則本回條將會作廢。

3. If the Company does not receive a functional email address in your reply, you will 如本公司沒有收到閣下的有效電子郵件地址，閣下將無法收到有關發佈公司

4. If you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered. 如閣下透過一或多個QR碼、電郵、回覆表格或其他方法提供多於一個的電子郵件地址，只有閣下最後提供的電子郵件地址將會被用於登記。

5. If you mark "✓" in the box in Option 3, no email address will be registered and only Corporate Communications# in printed form will be received.

如閣下在選項 3 方格內劃上「✓」號，將不會有電子郵件地址被登記，只會收取公司通訊*的印刷本。

6. For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.

為免存疑，在本回條上的任何額外指示，本公司將不予處理。

* For identification purpose only 僅供識別

For identification purpose only 僅供識別

Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form.

除非另有註明，公司通訊乃指本公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

(i) "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").

(ii) Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications⁵ and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.

閣下持有的公司證券有關的其他事宜上與 閣下聯絡。 閣下是自願向本公司提供個人資料。若 閣下未能提供足夠資料，本公司可能無法處理 閣下在本回條上所述的指示及/或要求。

(iii) Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrars, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.

(iv) You have the right to request access to and/or correction of your Personal Data in compliance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrars at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at PrivacyOfficer@computershare.com.hk.
閣下有權根據《私隱條例》的條文查閱及/或修改 閣下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至股份過戶處（地址為香港灣仔皇后大道東 183 號合和中心 17M 樓）向香港聯私主提出，或發送電郵至 PrivacyOfficer@computershare.com.hk。

Mailing Label 郵寄標籤

share Hong Kong Investor Serv
香港中央證券登記有限公司

Freepost No. 簡便回郵號碼：37
Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

當閣下寄回此回條時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。